When was Kezar Life Sciences founded?

Kezar Life Sciences was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Kezar Life Sciences located?

Kezar Life Sciences is headquartered in San Francisco, United States. It is registered at South San Francisco, California.

Who is the current CEO of Kezar Life Sciences?

Marcos Ortiz of Kezar Life Sciences. They have also founded 1 company.

How many employees does Kezar Life Sciences have?

As of Jun 30, 2026, the latest employee count at Kezar Life Sciences is 23.

Is Kezar Life Sciences a funded company?

Kezar Life Sciences is a funded company, having raised a total of $78.4M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 22, 2015.

When was the latest funding round of Kezar Life Sciences?

Kezar Life Sciences' latest funding was a $***** Series B round on Jul 21, 2017, with participation from 10 investors.

What is the annual revenue of Kezar Life Sciences?

Annual revenue of Kezar Life Sciences is between $1M and $10M as on Dec 31, 2023

Where does Kezar Life Sciences rank among its competitors?

Kezar Life Sciences ranks 47th amongst 414 active competitors, of which 139 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was DBV Technologies, which secured $307M in Apr, 2025.

Who are the top competitors of Kezar Life Sciences?

Kezar Life Sciences' top competitors include Biogen, Abcellera Biologics and Sana Biotechnology. Among them, DBV Technologies secured the most recent funding round in April, 2025.

Kezar Life Sciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Kezar Life Sciences is an acquired company based in San Francisco (United States), founded in 2015 by Marcos Ortiz. It operates as a Developer of drugs targeting protein homeostasis for autoimmune disorders. Kezar Life Sciences has raised $78.4M in funding from investors like Nasdaq, Morningside and EcoR1. The company has 414 active competitors, including 139 funded and 116 that have exited. Its top competitors include companies like Biogen, Abcellera Biologics and Sana Biotechnology.

Company Details

Developer of drugs targeting protein homeostasis for autoimmune disorders. The company develops therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. The product pipeline includes KZR-616 and KZR-261 for autoimmune disease and hematologic tumor types.

Website: kezarlifesciences.com
Registered Address: South San Francisco, California

Key Metrics

Founded Year

2015

Location

San Francisco, United States

Stage

Acquired

Total Funding

$78.4M in 2 rounds

Latest Funding Round

Series B, Jul 21, 2017, $*****

Investors

Nasdaq & 16 more

Ranked

47^th among 414 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2023

Employee Count

23 as on Jun 30, 2026

Similar Companies

Biogen & 484 more

Exit Details

Acquired by Aurinia Pharmaceuticals (Mar 30, 2026)

View Kezar Life Sciences' full profile

Kezar Life Sciences is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
KEZAR LIFE SCIENCES, INC. CIN: 1645666 , United States, Active	Feb 18, 2015	$1M - $10M (As on Dec 31, 2023)	-	-
Kezar Life Sciences CIN: 473366145 , United States, Active	Dec 31, 1999	-	56 (As on Dec 31, 2024)	-

Kezar Life Sciences got acquired by Aurinia Pharmaceuticals on Mar 30, 2026.

Click here to take a look at Kezar Life Sciences's acquisition in detail

Kezar Life Sciences has raised a total funding of $78.4M over 2 rounds. Its first funding round was on Jun 22, 2015. Its latest funding round was a Series B round on Jul 21, 2017 for $*****. 10 investors participated in its latest round. Kezar Life Sciences has 17 institutional investors.

Here is the list of recent funding rounds of Kezar Life Sciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 21, 2017	4204251	Series B	8831963	2810354	2102109	4113808
Jun 22, 2015	4396002	Series A	3853261	4894520	EcoR1 & 4 more	2414984

Access funding benchmarks and valuations. Sign up today!

View details of Kezar Life Sciences's funding rounds and investors

The founders of Kezar Life Sciences is Marcos Ortiz.

Here are the details of Kezar Life Sciences' key team members:

Marcos Ortiz: Co-Founder and CEO of Kezar Life Sciences and founder of 1 other company.

View details of Kezar Life Sciences's Founder profiles and Board Members

Kezar Life Sciences' employee count trend

Kezar Life Sciences has 23 employees as of Jun 26. Here is Kezar Life Sciences's employee count trend over the years:

Employee count trend for Kezar Life Sciences

Uncover Kezar Life Sciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kezar Life Sciences include Biogen, Abcellera Biologics and Sana Biotechnology. Here is the list of Top 10 competitors of Kezar Life Sciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
2nd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	76/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
5th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
6th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Fidelity Investments & 13 others	71/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
8th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	Woodford Investment Management, General Atlantic ... & 50 others	69/100
9th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
10th	DBV Technologies 2002, Bagneux (France), Public	Developer of products for the treatment of various kinds of food allergies	$68.9M	Sofinnova Partners, Apax & 16 others	68/100
47th	Kezar Life Sciences 2015, San Francisco (United States), Acquired	Developer of drugs targeting protein homeostasis for autoimmune disorders	$78.4M	Amgen Business Development, Cowen & 15 others	54/100